Infiltrative cardiomyopathies

Clinical Medicine Insights: Cardiology

Volumn 9, Issue , 2015, Pages 29-38

  Bejar, David ^a   Colombo, Paolo C ^a   Latif, Farhana ^a   Yuzefpolskaya, Melana ^a  

^a Department of Medicine   (United States)

Author keywords

Amyloidosis; Hemochromatosis; Infiltrative cardiomyopathy; Sarcoidosis

Indexed keywords

AZATHIOPRINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DIFLUNISAL; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; PREDNISONE; TAFAMIDIS; THALIDOMIDE;

ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CHELATION THERAPY; CLINICAL EVALUATION; CLINICAL FEATURE; DANON DISEASE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FABRY DISEASE; FRIEDREICH ATAXIA; HEART AMYLOIDOSIS; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEMOCHROMATOSIS; HUMAN; IRON OVERLOAD CARDIOMYOPATHY; MOLECULAR PATHOLOGY; OXIDATIVE STRESS; PHLEBOTOMY; PROGNOSIS; SARCOIDOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL TRANSPLANTATION; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT PLANNING;

EID: 84937393246     PISSN: None     EISSN: 11795468     Source Type: Journal    
DOI: 10.4137/CMC.S19706     Document Type: Article

References (121)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003; 349(6): 583-96.
2. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006; 166(17): 1805-13.
3. Seward JB, Casaclang-Verzosa G. Infiltrative cardiovascular diseases cardiomyopathies that look alike. J Am Coll Cardiol. 2010; 55(17): 1769-79.
4. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004; 22(18): 3751-7.
5. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012; 30(9): 989-95.
6. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012; 126(10): 1286-300.
7. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med. 1997; 336(7): 466-73.
8. Buxbaum JN, Tagoe C, Gallo G, Walker JR, Kurian S, Salomon DR. Why are some amyloidoses systemic? Does hepatic "chaperoning at a distance" prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis? FASEB J. 2012; 26(6): 2283-93.
9. Ruberg FL, Maurer MS, Judge DP, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012; 164(2): 222-8. e1.
10. Dubrey SW, Cha K, Simms RW, Skinner M, Falk RH. Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol. 1996; 77(4): 313-5.
11. Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med. 1997; 336(4): 267-76.
12. Chew C, Ziady GM, Raphael MJ, Oakley CM. The functional defect in amyloid heart disease: the "stiff heart" syndrome. Am J Cardiol. 1975; 36(4): 438-44.
13. Klein AL, Hatle LK, Burstow DJ, et al. Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol. 1989; 13(5): 1017-26.
14. Ridolfi RL, Bulkley BH, Hutchins GM. The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients. Am J Med. 1977; 62(5): 677-86.
15. Smith RR, Hutchins GM. Ischemic heart disease secondary to amyloidosis of intramyocardial arteries. Am J Cardiol. 1979; 44(3): 413-7.
16. Neben-Wittich MA, Wittich CM, Mueller PS, Larson DR, Gertz MA, Edwards WD. Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J Med. 2005; 118(11): 1287.
17. Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol. 2008; 103(3): 776-87.
18. Kurita N, Kotera N, Ishimoto Y, et al. AA amyloid nephropathy with predominant vascular deposition in Crohn's disease. Clin Nephrol. 2013; 79(3): 229-32.
19. Shin SC, Robinson-Papp J. Amyloid neuropathies. Mt Sinai J Med. 2012; 79(6): 733-48.
20. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis. 2010; 52(4): 347-61.
21. Kraemer BF, Seizer P, Geisler T, et al. Persistent troponin elevation in a patient with cardiac amyloidosis. Clin Cardiol. 2009; 32(11): E39-42.
22. Cantwell RV, Aviles RJ, Bjornsson J, et al. Cardiac amyloidosis presenting with elevations of cardiac troponin I and angina pectoris. Clin Cardiol. 2002; 25(1): 33-7.
23. Chamarthi B, Dubrey SW, Cha K, Skinner M, Falk RH. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol. 1997; 80(9): 1242-5.
24. Mathew V, Olson LJ, Gertz MA, Hayes DL. Symptomatic conduction system disease in cardiac amyloidosis. Am J Cardiol. 1997; 80(11): 1491-2.
25. Navarro JF, Rivera M, Ortuno J. Cardiac tamponade as presentation of systemic amyloidosis. Int J Cardiol. 1992; 36(1): 107-8.
26. Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007; 116(21): 2420-6.
27. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005; 95(4): 535-7.
28. Tsang W, Lang RM. Echocardiographic evaluation of cardiac amyloid. Curr Cardiol Rep. 2010; 12(3): 272-6.
29. Lee GY, Kim K, Choi JO, et al. Cardiac amyloidosis without increased left ventricular wall thickness. Mayo Clin Proc. 2014; 89(6): 781-9.
30. Falk RH, Plehn JF, Deering T, et al. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol. 1987; 59(5): 418-22.
31. Baccouche H, Maunz M, Beck T, et al. Differentiating cardiac amyloidosis and hypertrophic cardiomyopathy by use of three-dimensional speckle tracking echocardiography. Echocardiography. 2012; 29(6): 668-77.
32. Koyama J, Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging. 2010; 3(4): 333-42.
33. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging. 2010; 3(2): 155-64.
34. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005; 46(6): 1076-84.
35. Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013; 6(2): 195-201.
36. Ardehali H, Qasim A, Cappola T, et al. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J. 2004; 147(5): 919-23.
37. Cooper LT, Baughman KL, Feldman AM, et al; American Heart Association, American College of Cardiology, European Society of Cardiology, Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology. The role of endomyocardial biopsy in the management of cardiovascular disease a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007; 50(19): 1914-31.
38. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005; 112(13): 2047-60.
39. Ansari-Lari MA, Ali SZ. Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test? Diagn Cytopathol. 2004; 30(3): 178-81.
40. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012; 1(2): e000364.
41. Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol. 2015; 12(2): 91-102.
42. Gertz MA, Skinner M, Connors LH, Falk RH, Cohen AS, Kyle RA. Selective binding of nifedipine to amyloid fibrils. Am J Cardiol. 1985; 55(13 pt 1): 1646.
43. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation. 1981; 63(6): 1285-8.
44. Varr BC, Zarafshar S, Coakley T, et al. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm. 2014; 11(1): 158-62.
45. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol. 2011; 29(14): 1924-33.
46. Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012; 119(19): 4391-4.
47. Maurer MS, Raina A, Hesdorffer C, et al. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation. 2007; 83(5): 539-45.
48. Dubrey SW, Davidoff R, Skinner M, Bergethon P, Lewis D, Falk RH. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation. 1997; 64(1): 74-80.
49. Raichlin E, Daly RC, Rosen CB, et al. Combined heart and liver transplantation: a single-center experience. Transplantation. 2009; 88(2): 219-25.
50. Nardo B, Beltempo P, Bertelli R, et al. Combined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center. Transplant Proc. 2004; 36(3): 645-7.
51. Berk JL, Suhr OB, Obici L, et al; Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013; 310(24): 2658-67.
52. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012; 79(8): 785-92.
53. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013; 369(9): 819-29.
54. Ackermann EJ, Guo S, Booten S, et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid. 2012; 19(Suppl 1): 43-4.
55. Kristen AV, Lehrke S, Buss S, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol. 2012; 101(10): 805-13.
56. Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008; 31(2): 372-9.
57. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978; 58(6): 1204-11.
58. Sekhri V, Sanal S, Delorenzo LJ, Aronow WS, Maguire GP. Cardiac sarcoidosis: a comprehensive review. Arch Med Sci. 2011; 7(4): 546-54.
59. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977; 63(1): 86-108.
60. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014; 11(7): 1304-23.
61. Matsui Y, Iwai K, Tachibana T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci. 1976; 278: 455-69.
62. Sekiguchi M, Numao Y, Imai M, Furuie T, Mikami R. Clinical and histopathological profile of sarcoidosis of the heart and acute idiopathic myocarditis. Concepts through a study employing endomyocardial biopsy. I. Sarcoidosis. Jpn Circ J. 1980; 44(4): 249-63.
63. Doughan AR, Williams BR. Cardiac sarcoidosis. Heart. 2006; 92(2): 282-8.
64. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord. 2007; 27: 89-102.
65. Judson MA, Costabel U, Drent M, et al; Organ Assessment Instrument Investigators TW. The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis. 2014; 31(1): 19-27.
66. Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999; 138(2 pt 1): 299-302.
67. Burstow DJ, Tajik AJ, Bailey KR, DeRemee RA, Taliercio CP. Two-dimensional echocardiographic findings in systemic sarcoidosis. Am J Cardiol. 1989; 63(7): 478-82.
68. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005; 45(10): 1683-90.
69. Youssef G, Beanlands RSB, Birnie DH, Nery PB. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart. 2011; 97(24): 2078-87.
70. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013; 6(4): 501-11.
71. Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008; 35(5): 933-41.
72. Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest. 2012; 141(1): 154-62.
73. Yazaki Y, Isobe M, Hiroe M, et al; Central Japan Heart Study Group. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001; 88(9): 1006-10.
74. Yodogawa K, Seino Y, Ohara T, Takayama H, Katoh T, Mizuno K. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011; 16(2): 140-7.
75. Vignaux O, Dhote R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest. 2002; 122(6): 1895-901.
76. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J. 2009; 157(1): 9-21.
77. Zaidi AR, Zaidi A, Vaitkus PT. Outcome of heart transplantation in patients with sarcoid cardiomyopathy. J Heart Lung Transplant. 2007; 26(7): 714-7.
78. Perkel D, Czer LS, Morrissey RP, et al. Heart transplantation for end-stage heart failure due to cardiac sarcoidosis. Transplant Proc. 2013; 45(6): 2384-6.
79. Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med. 1993; 328(22): 1616-20.
80. Crownover BK, Covey CJ. Hereditary hemochromatosis. Am Fam Physician. 2013; 87(3): 183-90.
81. Fletcher LM, Halliday JW. Haemochromatosis: understanding the mechanism of disease and implications for diagnosis and patient management following the recent cloning of novel genes involved in iron metabolism. J Intern Med. 2002; 251(3): 181-92.
82. Smith LH Jr. Pumping iron. West J Med. 1995; 162(4): 370-1.
83. Kremastinos DT, Farmakis D, Aessopos A, et al. β-thalassemia cardiomyopathy: history, present considerations, and future perspectives. Circ Heart Fail. 2010; 3(3): 451-8.
84. Gladwin MT, Sachdev V. Cardiovascular abnormalities in sickle cell disease. J Am Coll Cardiol. 2012; 59(13): 1123-33.
85. Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. Circulation. 2011; 124(20): 2253-63.
86. Gulati V, Harikrishnan P, Palaniswamy C, Aronow WS, Jain D, Frishman WH. Cardiac involvement in hemochromatosis. Cardiol Rev. 2014; 22(2): 56-68.
87. Horwitz LD, Rosenthal EA. Iron-mediated cardiovascular injury. Vasc Med. 1999; 4(2): 93-9.
88. Case records of the Massachusetts general hospital. Weekly clinicopathological exercises. Case 31-1994. A 25-year-old man with the recent onset of diabetes mellitus and congestive heart failure. N Engl J Med. 1994; 331(7): 460-6.
89. Olson LJ, Edwards WD, Holmes DR Jr, Miller FA Jr, Nordstrom LA, Baldus WP. Endomyocardial biopsy in hemochromatosis: clinicopathologic correlates in six cases. J Am Coll Cardiol. 1989; 13(1): 116-20.
90. Wang TL, Chen WJ, Liau CS, Lee YT. Sick sinus syndrome as the early manifestation of cardiac hemochromatosis. J Electrocardiol. 1994; 27(1): 91-6.
91. Aessopos A, Kati M, Farmakis D, Polonifi E, Deftereos S, Tsironi M. Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine. Int J Hematol. 2007; 86(3): 212-5.
92. Kremastinos DT, Tsiapras DP, Tsetsos GA, Rentoukas EI, Vretou HP, Toutouzas PK. Left ventricular diastolic Doppler characteristics in beta-thalassemia major. Circulation. 1993; 88(3): 1127-35.
93. Wood JC. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol. 2007; 14(3): 183-90.
94. Carpenter JP, He T, Kirk P, et al. On T2* magnetic resonance and cardiac iron. Circulation. 2011; 123(14): 1519-28.
95. Penugonda N. Cardiac MRI in infiltrative disorders: a concise review. Curr Cardiol Rev. 2010; 6(2): 134-6.
96. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009; 120(20): 1961-8.
97. Wood JC. Cardiac iron across different transfusion-dependent diseases. Blood Rev. 2008; 22(Suppl 2): S14-21.
98. Cooper LT, Baughman KL, Feldman AM, et al; American Heart Association, American College of Cardiology, European Society of Cardiology. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007; 116(19): 2216-33.
99. Dabestani A, Child JS, Henze E, et al. Primary hemochromatosis: anatomic and physiologic characteristics of the cardiac ventricles and their response to phlebotomy. Am J Cardiol. 1984; 54(1): 153-9.
100. Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y. Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol. 2010; 56(13): 1001-12.
101. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004; 127(3): 348-55.
102. Caines AE, Kpodonu J, Massad MG, et al. Cardiac transplantation in patients with iron overload cardiomyopathy. J Heart Lung Transplant. 2005; 24(4): 486-8.
103. Olivieri NF, Liu PP, Sher GD, et al. Brief report: combined liver and heart transplantation for end-stage iron-induced organ failure in an adult with homozygous beta-thalassemia. N Engl J Med. 1994; 330(16): 1125-7.
104. Pieroni M, Chimenti C, De Cobelli F, et al. Fabry's disease cardiomyopathy echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol. 2006; 47(8): 1663-71.
105. Morrissey RP, Philip KJ, Schwarz ER. Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy. Cardiovasc J Afr. 2011; 22(1): 38-44.
106. Anastasakis A, Sevdalis E, Papatheodorou E, Stefanadis C. Anderson-Fabry disease: a cardiomyopathy that can be cured. Hellenic J Cardiol. 2011; 52(4): 316-26.
107. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Clin Invest. 2004; 34(3): 236-42.
108. Namdar M, Steffel J, Vidovic M, et al. Electrocardiographic changes in early recognition of Fabry disease. Heart. 2011; 97(6): 485-90.
109. De Cobelli F, Esposito A, Belloni E, et al. Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy. AJR Am J Roentgenol. 2009; 192(3): W97-102.
110. Weidemann F, Sanchez-Niño MD, Politei J, et al. Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis. 2013; 8: 116.
111. Maron BJ. A phenocopy of sarcomeric hypertrophic cardiomyopathy: LAMP2 cardiomyopathy (Danon disease) from China. Eur Heart J. 2012; 33(5): 570-2.
112. Maron BJ, Roberts WC, Arad M, et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA. 2009; 301(12): 1253-9.
113. Nucifora G, Miani D, Piccoli G, Proclemer A. Cardiac magnetic resonance imaging in Danon disease. Cardiology. 2012; 121(1): 27-30.
114. Echaniz-Laguna A, Mohr M, Epailly E, et al. Novel LAMP-2 gene mutation and successful treatment with heart transplantation in a large family with Danon disease. Muscle Nerve. 2006; 33(3): 393-7.
115. Durr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med. 1996; 335(16): 1169-75.
116. Delatycki MB, Corben LA. Clinical features of Friedreich ataxia. J Child Neurol. 2012; 27(9): 1133-7.
117. Dutka DP, Donnelly JE, Nihoyannopoulos P, Oakley CM, Nunez DJ. Marked variation in the cardiomyopathy associated with Friedreich's ataxia. Heart. 1999; 81(2): 141-7.
118. Unverferth DV, Schmidt WR II, Baker PB, Wooley CF. Morphologic and functional characteristics of the heart in Friedreich's ataxia. Am J Med. 1987; 82(1): 5-10.
119. Delatycki MB, Paris DB, Gardner RJ, et al. Clinical and genetic study of Friedreich ataxia in an Australian population. Am J Med Genet. 1999; 87(2): 168-74.
120. Morvan D, Komajda M, Doan LD, et al. Cardiomyopathy in Friedreich's ataxia: a Doppler-echocardiographic study. Eur Heart J. 1992; 13(10): 1393-8.
121. Weidemann F, Stork S, Liu D, et al. Cardiomyopathy of Friedreich ataxia. J Neurochem. 2013; 126(Suppl 1): 88-93.